Blueprint Medicines

company

About

Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.

Details

Last Funding Type
Series C
Last Funding Money Raised
$50M
Industries
Bioinformatics,Biotechnology,Health Care,Medical
Founded date
Jan 1, 2011
Number Of Employee
251 - 500
Operating Status
Active
Stock Symbol
nasdaq:BPMC
Legal Name
Blueprint Medicines Corporation

Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat.

Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data revolution: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
9
$1.26B
Blueprint Medicines has raised a total of $1.26B in funding over 2 rounds. Their latest funding was raised on Mar 27, 2019 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 27, 2019 Post-IPO Equity $327.20M Detail
Dec 11, 2017 Post-IPO Equity $325.50M Detail
Mar 29, 2017 Post-IPO Equity $215.60M Detail
Dec 6, 2016 Post-IPO Equity $134.50M Detail
Apr 27, 2015 IPO $147M Detail

Investors

Number of Lead Investors
Number of Investors
4
15
Blueprint Medicines is funded by 15 investors. Partner Fund Management and Eight Roads Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Partner Fund Management Yes Series C
Eight Roads Ventures Yes Series Unknown
Casdin Capital Series C
Cowen Group Series C
Fidelity Biosciences Series C
Nextech Invest Series C
Perceptive Advisors Series C
RA Capital Management Series C
Redmile Group Series C
Sabby Capital Series C

Employee Profiles

Number of Employee Profiles
27
Blueprint Medicines has 27 current employee profiles, including Executive Percy Carter
Executive
Executive
Advisor
Executive
Executive

Acquisition

Blueprint Medicines has acquired 1 organizations. Their most recent acquisition was Lengo Therapeutics on Nov 29, 2021. They acquired Lengo Therapeutics for $250M.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition $ 250M Detail